Fu Siong Ng1, Ondřej Toman2, Jan Petru3, Petr Peichl4, Roger A Winkle5, Vivek Y Reddy6, Petr Neuzil3, R Hardwin Mead5, Norman A Qureshi7, Zachary I Whinnett7, David W Bourn8, M Brent Shelton8, Josef Kautzner4, Arjun D Sharma8, Meleze Hocini9, Michel Haïssaguerre9, Nicholas S Peters7, Igor R Efimov10. 1. National Heart & Lung Institute, Imperial College London, London, United Kingdom; Imperial College Healthcare NHS Trust, London, United Kingdom; Chelsea & Westminster Hospital NHS Foundation Trust, London, United Kingdom. Electronic address: f.ng@imperial.ac.uk. 2. University Hospital Brno, Brno, Czech Republic. 3. Na Homolce, Prague, Czech Republic. 4. Institut Klinické a Experimentální Medicíny, Prague, Czech Republic. 5. Sequoia Hospital, Redwood City, California, USA. 6. Mount Sinai School of Medicine, New York, New York, USA. 7. National Heart & Lung Institute, Imperial College London, London, United Kingdom; Imperial College Healthcare NHS Trust, London, United Kingdom. 8. Cardialen, Inc, Minneapolis, Minnesota, USA. 9. Hôpital Cardiologique du Haut-Lévêque, Bordeaux-Pessac, Bordeaux, France. 10. George Washington University, Washington, DC, USA. Electronic address: efimov@gwu.edu.
Abstract
OBJECTIVES: This first-in-human feasibility study was undertaken to translate the novel low-voltage MultiPulse Therapy (MPT) (Cardialen, Inc., Minneapolis, Minnesota), which was previously been shown to be effective in preclinical studies in terminating atrial fibrillation (AF), into clinical use. BACKGROUND: Current treatment options for AF, the most common arrhythmia in clinical practice, have limited success. Previous attempts at treating AF by using implantable devices have been limited by the painful nature of high-voltage shocks. METHODS: Forty-two patients undergoing AF ablation were recruited at 6 investigational centers worldwide. Before ablation, electrode catheters were placed in the coronary sinus, right and/or left atrium, for recording and stimulation. After the induction of AF, MPT, which consists of up to a 3-stage sequence of far- and near-field stimulation pulses of varied amplitude, duration, and interpulse timing, was delivered via temporary intracardiac leads. MPT parameters and delivery methods were iteratively optimized. RESULTS: In the 14 patients from the efficacy phase, MPT terminated 37 of 52 (71%) of AF episodes, with the lowest median energy of 0.36 J (interquartile range [IQR]: 0.14 to 1.21 J) and voltage of 42.5 V (IQR: 25 to 75 V). Overall, 38% of AF terminations occurred within 2 seconds of MPT delivery (p < 0.0001). Shorter time between AF induction and MPT predicted success of MPT in terminating AF (p < 0.001). CONCLUSIONS: MPT effectively terminated AF at voltages and energies known to be well tolerated or painless in some patients. Our results support further studies of the concept of implanted devices for early AF conversion to reduce AF burden, symptoms, and progression.
OBJECTIVES: This first-in-human feasibility study was undertaken to translate the novel low-voltage MultiPulse Therapy (MPT) (Cardialen, Inc., Minneapolis, Minnesota), which was previously been shown to be effective in preclinical studies in terminating atrial fibrillation (AF), into clinical use. BACKGROUND: Current treatment options for AF, the most common arrhythmia in clinical practice, have limited success. Previous attempts at treating AF by using implantable devices have been limited by the painful nature of high-voltage shocks. METHODS: Forty-two patients undergoing AF ablation were recruited at 6 investigational centers worldwide. Before ablation, electrode catheters were placed in the coronary sinus, right and/or left atrium, for recording and stimulation. After the induction of AF, MPT, which consists of up to a 3-stage sequence of far- and near-field stimulation pulses of varied amplitude, duration, and interpulse timing, was delivered via temporary intracardiac leads. MPT parameters and delivery methods were iteratively optimized. RESULTS: In the 14 patients from the efficacy phase, MPT terminated 37 of 52 (71%) of AF episodes, with the lowest median energy of 0.36 J (interquartile range [IQR]: 0.14 to 1.21 J) and voltage of 42.5 V (IQR: 25 to 75 V). Overall, 38% of AF terminations occurred within 2 seconds of MPT delivery (p < 0.0001). Shorter time between AF induction and MPT predicted success of MPT in terminating AF (p < 0.001). CONCLUSIONS: MPT effectively terminated AF at voltages and energies known to be well tolerated or painless in some patients. Our results support further studies of the concept of implanted devices for early AF conversion to reduce AF burden, symptoms, and progression.
Authors: Wenwen Li; Ajit H Janardhan; Vadim V Fedorov; Qun Sha; Richard B Schuessler; Igor R Efimov Journal: Circ Arrhythm Electrophysiol Date: 2011-10-06
Authors: H J Wellens; C P Lau; B Lüderitz; M Akhtar; A L Waldo; A J Camm; C Timmermans; H F Tse; W Jung; L Jordaens; G Ayers Journal: Circulation Date: 1998-10-20 Impact factor: 29.690
Authors: J Christoph Geller; Sven Reek; Carl Timmermans; Torsten Kayser; Hung Fat Tse; Christian Wolpert; Werner Jung; A John Camm; Chu Pak Lau; Hein J J Wellens; Helmut U Klein Journal: Eur Heart J Date: 2003-12 Impact factor: 29.983
Authors: Stefan Luther; Flavio H Fenton; Bruce G Kornreich; Amgad Squires; Philip Bittihn; Daniel Hornung; Markus Zabel; James Flanders; Andrea Gladuli; Luis Campoy; Elizabeth M Cherry; Gisa Luther; Gerd Hasenfuss; Valentin I Krinsky; Alain Pumir; Robert F Gilmour; Eberhard Bodenschatz Journal: Nature Date: 2011-07-13 Impact factor: 49.962